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Background: Despite multimodal therapy esophageal cancer often presents with poor prognosis. To improve
outcome, tumor angiogenesis and anti-angiogenic therapeutic agents have recently gained importance. However,
patient subgroups who benefit from anti-angiogenic therapy are not yet defined. In this retrospective exploratory
study we investigated 9 angiogenic factors in patients’ serum and tissue samples with regard to their association
with clinicopathological parameters, prognosis and response in patients with locally advanced preoperatively
treated esophageal cancer.
Methods: From 2007 to 2012 preoperative serum and corresponding tumor tissue (n = 54), only serum (n = 20)
or only tumor tissue (n = 4) were collected from esophageal squamous cell carcinoma (SCC) (n = 34) and
adenocarcinoma of the esophagogastric junction (AEG) (n = 44) staged cT3/4NanyM0/x after preoperative
chemo(radio)therapy. Angiogenic cytokine levels in both tissue and serum were measured by multiplex immunoassay.
Results: Median survival in all patients was 28.49 months. No significant difference was found in survival
between SCC and AEG (p = 0.90). 26 patients were histopathological responders. Histopathological response
was associated with prognosis (p = 0.05).
Angiogenic factors were associated with the following clinicopathological factors: tumor tissue expression of
Angiopoietin-2 and Follistatin was higher in SCC compared to AEG (p = 0.022 and p = 0.001).
High HGF and Follistatin expression in the tumor tissue was associated with poor prognosis in all patients (p = 0.037 and
p = 0.036). No association with prognosis was found in the patients’ serum. Neither patients’ serum nor tumor tissue
showed an association between angiogenic factors and response to neoadjuvant therapy.
Conclusion: Two angiogenic factors (HGF and Follistatin) in posttherapeutic tumor tissue are associated with prognosis in
esophageal cancer patients. Biological differences of AEG and SCC with respect to angiogenesis
were evident by the different expression of 2 angiogenic factors. Results are promising and should be pursued
prospectively, optimally sequentially pre- and posttherapeutically.
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Esophageal cancer is known for its aggressive tumor
growth and poor prognosis. 5-year overall survival rates
vary between 15-25% [1]. This poor outcome is linked to
the fact that the disease is often detected in an advanced
state when dysphagia occurs, often making a cure by
surgical resection difficult [2,3]. To improve this fatal* Correspondence: thomas1.schmidt@med.uni-heidelberg.de
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unless otherwise stated.situation, patients with locoregional disease receive neo-
adjuvant chemo- or chemoradiotherapy before undergo-
ing surgery, which has been shown to provide a survival
benefit [4-6]. Considering the fact that only patients who
respond to this neoadjuvant therapy have a clear survival
advantage, and that nonresponding patients do not, the
prediction of response and prognosis is of highest inter-
est [7-9]. Response rates differ depending on the chosen
therapeutic regimen from 20–50% [7]. Even though dif-
ferent prediction algorithms exist, they are not yet used
in clinical practice. Recent studies indicated that factorsntral. This is an Open Access article distributed under the terms of the Creative
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patients’ response and outcome [10]. Tumor angiogen-
esis, the formation of new blood vessels within a tumor
presents an important part of the tumor microenviron-
ment. Beyond a certain size, tumors are not further sup-
ported by diffusion, but undergo an “angiogenic switch”,
which supports further tumor growth and metastasis
[11-13]. Angiogenesis within solid tumors is a complex
process, involving many different factors that are active
at different time points [14]. The significance of the
resulting proangiogenic environment has led to the de-
velopment of anti-angiogenic therapeutic agents against
the main angiogenic factors. As first anti-angiogenic
therapy an antibody, bevacizumab, was developed target-
ing against the prototypic angiogenic molecule vascular
endothelial growth factor (VEGF-A). Addition of bev-
acizumab in metastatic colorectal cancers showed a
survival benefit when added to Irinotecan and 5-
Fluoruracile in a Phase III trial [15]. In Phase II stud-
ies the use of bevacizumab in patients with esophageal
carcinoma in combination with Cisplatin and Capecit-
abine was associated with a higher response rate and
longer progression-free survival. However, these trials
failed to show a benefit of overall survival in patients
with esophageal cancer [16]. In the REGARD trial it
was recently shown that treatment with ramicirumab
monotherapy, an antibody against VEGF receptor 2
(VEGFR-2), can prolong survival in patients with ad-
vanced gastric and esophageal cancer.
As a crucial element in esophageal cancer angiogenesis
is linked to tumor growth and metastasis [17]. Angio-
genic factors previously described in esophageal cancer
are Vascular endothelial growth factor (VEGF), hepato-
cyte growth factor (HGF), fibroblast growth factor
(FGF), midkine and thymidine phosphorylase [17]. Prog-
nostic impact has been reported for VEGF, FGF and
HGF. A recent meta-analysis on data of 29 studies and
2345 patients reexamined the role of VEGF in esopha-
geal cancer. Esophageal SCC patients with elevated
levels had a 1.82-fold greater risk of death, but no asso-
ciation with poor survival in AEG was shown [18]. Sev-
eral studies indicate that HGF is overexpressed in SCC
tissue specimen and serum levels are associated with
survival and clinicopathological parameters such as dis-
tant metastases [19-21]. Another angiogenic factor asso-
ciated with poor survival is FGF [22,23].
The aim of this retrospective exploratory study was to
investigate the complex angiogenic cytokine expression
both in tissue and serum at the time of resection in pa-
tients with neoadjuvantly treated esophageal cancer. To
elucidate the complexity of this network a commercial
multiplex assay for 9 angiogenic factors was utilized.
Different cytokine profiles linked to therapeutic out-
come could help establish anti-angiogenic targets thatcombined with chemo(radio)therapy could improve
response to therapy in a defined subgroup of patients.
Methods
Patient data
78 patients with esophageal squamous cell carcinoma
(n = 34) and adenocarcinoma of the gastroesophageal
junction (AEG I/II) (n = 44) were included in the study.
These patients were treated in the Department of
Surgery, University of Heidelberg, Germany between
2007 and 2012. All patients underwent neoadjuvant
chemo(radio)therapy followed by resection or explora-
tive operation according to the current guidelines.
Patients received neoadjuvant therapy as mostly on an
out-patient basis from their oncologist. Therapies regi-
mens were decided by the oncologist or after presenta-
tion at an interdisciplinary tumor board.
Patients with adenocarcinoma (44 pts) of the gastro-
esophageal junction were treated with either Epirubicin
containing regimens (EOX, ECF) (29/44; 65,9%) or
alternatively with a 5-FU/platinum based regime (FLOT/
FLO/FOLFOX/PLF) (9/44; 20,5%). 5 patients (5/44;
11,4%) with AEG received chemoradiotherapy, 1 patient
received a Taxol based chemotherapy. Chemoradiother-
apy combined with Cisplatin and 5-Fluoruracil was
given to all patients (34 pts) with esophageal squamous
cell carcinoma (34/34; 100%). Details on neoadjuvant
treatment regimens are shown in Additional file 1:
Table S1A.
As preoperative staging all patients received a CT scan
and an endoscopy. Patients with a decrease of tumor
mass in endoscopy and a >50% decline in wall thickness
seen in the CT and/or endoscopic ultrasound were de-
fined as clinical responders [24].
Most patients underwent abdominothoracic en bloc
esophagectomy including a 2-field-lymphadenectomy
with anastomosis either in the anterior or in the poster-
ior mediastinum or a transhiatal esophagectomy with
anastomosis in the neck. Patients with AEG II received a
transhiatal gastrectomy with D2-lymphadenectomy. Op-
erative procedures are shown in Additional file 1: Table
S1B. 14 Patients received adjuvant therapy. 12 received
adjuvant chemotherapy, 1 additive chemotherapy and 1
palliative chemoradiotherapy.
All patients gave written informed consent. The study
protocol was approved by the Ethical Committee of the
University of Heidelberg.
Follow up
Most patients received follow-up examinations in the
National Center for Tumor Diseases, Heidelberg. Patient
follow-up was performed quarterly in the first year, every
six months in the second and third year and annually in
the fourth or fifth year after resection. In case of follow-
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and the oncologist was contacted by mail. Median
follow-up of the surviving patients was 40.62 months,
one patient was lost to follow-up.
Histopathology
Pathological specimens were analysed in the Department
of Pathology of the University Hospital Heidelberg.
Histopathological staging comprised TNM classification,
R-category and tumor regression rate (TRG). All pa-
tients were re-classified according to the 7th edition of
the TNM staging.
To specify TRG Becker regression score was used:
1a—complete regression (no residual tumor)
1b—subtotal regression (<10% residual tumor)
2—minor regression (10–50% residual tumor)
3—no regression (>50% residual tumor).
We classified patients with regression grades 1a and
1b as histopathological responders, those with grades 2
and 3 as non-responders. In addition we used 50% re-
sidual tumor as another cut-off point for response, to
take the limited number of patients into account.
Blood and tissue sampling and preparation
One day before tumor resection blood was collected in
serum tubes from a central venous catheter or by per-
ipheral venous sampling. Before blood was taken from
the central venous catheter the first 5 ml of the drawn
blood were discarded to avoid dilution with blocking sa-
line. To extract the serum the tubes were centrifugated
at 2.500 g for 10 minutes. Serum was then stored at
−80°C until analysis. Before analysis serum was diluted
1:4 with a sample diluent.
The tissue specimens were collected directly after
tumor resection and then stored at −80°C. Sections of
10 μm were cut with a cryotome. Sections were then
transferred into a lysis buffer. The concentration of the
lysed tissue samples was adjusted to 600 μg/ml.
Cytokine detection
We detected serum and tissue concentrations of Platelet
Endothelial Cell Adhesion Molecule 1 (PECAM-1),
Vascular Endothelial Growth Factor (VEGF), Leptin,
Angiopoietin-2 (Ang-2), Follistatin, Granulocyte-Colony
Stimulating Factor (GCSF), Hepatocyte Growth Factor
(HGF), Platelet-Derived Growth Factor (PDGF) and
Interleukin-8 (IL-8). Cytokine levels were measured
using the BioRad Bio-Plex Human Angiogenesis Assay
(Bio-Rad Laboratories, Inc., Hercules, CA 94547, USA)
and Luminex two-laser array reader (Bioplex200). Bio-
plex Manager 6.1. (Bio-Rad Laboratories, Inc., Hercules,
CA 94547, USA) was used to acquire standard curves
and concentrations.Statistical analysis
Continuous variables are expressed as median and inter
quartile ranges (IQR) with additional 95% confidence
interval. To compare differences in medians we used the
Mann–Whitney-U test or Kruskal-Wallis H-Test for
multiple comparisons between the groups. Additional
multiple ANOVA (MANOVA) testing was performed
for multiple hypothesis testing in multiple comparisons.
Categorical data is presented in absolute and relative
frequencies. Comparison was performed by the Chi-
square-test. To compare angiogenic cytokine levels we
used the median as a cut-off.
We measured overall survival from point of diagnosis
until death. The Kaplan Meier Method was performed
for survival analysis, for differences in survival time we
used the log-rank test. Results for overall survival were
confirmed with multi-variate Cox regression analysis.
Receiver-operating characteristic (ROC) curves and area
under the ROC curve (AUC) were used to assess the
diagnostic value of Follistatin and HGF. A ROC curve
was created to select the Youden’s index (Youden’s
index = sensitivity + specificity − 1), and the highest sen-
sitivity and specificity were selected as the cutoff values.
Statistical significance was taken as a p-value of <0.05
(two-tailed). All statistical analyses were done using
SPSS software version 20.0 (SPSS, Inc., Chicago, Illinois,
USA).
Results
Patients’ pretherapeutic and postoperative clinicopatho-
logical characteristics are displayed in Tables 1 and 2.
We included 78 patients, 34 (43.6%) with esophageal
squamous cell carcinoma and 44 (56.4%) with adenocar-
cinoma of the gastroesophageal junction (AEG I/II).
Prognostic clinicopathological factors
As relevant prognostic factors in all patients we found
the pN-category (p = 0.001). Additionally tumor re-
gression grade (TRG) was found to be a significant
prognostic factor in all patients (p = 0.052) and in
adenocarcinoma of the gastroesophageal junction (p =
0.048). Clinical and histopathological reponse and 3-
year survival rates of SCC and AEG are displayed in
Additional file 2: Table S2.
Correlation of angiogenic factors with clinicopathological
factors
Angiopoietin-2 and Follistatin protein levels within
the tumor tissue were associated with tumor type (p =
0.022 and p = 0.001). Patients with SCC had higher
levels of Angiopoietin-2 and Follistatin levels than pa-
tients with AEG (Table 3). Circulating angiogenic fac-
tors did not correlate with other clinicopathological
factors (Table 4).
Table 1 Pretherapeutic patients’ characteristics
Characteristics n % Median survival (IQR) 95%CI 3-Y-S (%) p value
Total, n 78 100,0% 28,5 (13,7;*) 42,7%
Age (years) 63 ± 7,8 (41–80)
Sex Male 62 79,5% 28,5 (13,8;*) 16,1 - 40,9 42,6% 0,711
Female 16 20,5% 29,1 (11,6;*) - 45,6%
Localisation AEG I/II 44 56,4% 28,5 (17,0;*) 19,2 - 37,8 37,7% 0,904
SCC 34 43,6% n.r. - 50,9%
cT Category cT1 0
cT2 5 6,4% n.r. - 60,0% 0,812
cT3 69 88,5% 23,8 (12,8;*) 15,9 - 31,7 42,8%
cT4 4 5,1% 36,7 (33,7;*) 31,9 - 41,5 33,3%
cN Category cN0 17 21,8% 30,6 (20,5;*) 15,5 - 45,7 37,8% 0,906
cN+ 61 78,2% 24,0 (12,3;*) 9,1 - 38,8 44,6%
cM Category cM0 67 85,9% 23,8 (12,8;*) 15,1 - 32,5 40,2% 0,317
cM1 11 14,1% n.r. - 57,3%
Grading G 1/2 32 41,0% 23,1 (11,0;*) 13,4 - 32,7 34,0% 0,428
G 3/4 38 48,7% 29,1 (13,8;*) - 45,5%
Lauren initial (AEG) Intestinal 26 59,1% 30,6 (17,0;*) 15,6 - 45,6 40,4% 0,620
Nonintestinal 13 29,5% 24,0 (20,3;*) 19,3 - 28,6 33,8%
Median Survival shown in months; n.r.: not reached; CI: confidence interval; 3-Y-S: 3-Year-Survival; IQR: inter quartile range (1st quartile; 3rd quartile (* 3rd quartile
not reached)).
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As shown in Tables 3 and 4 angiogenic cytokine levels ei-
ther circulating or within the tissue were not associated
with clinical response or TRG for all patients as well as in
the AEG and SCC subgroups (Additional file 3: Table S3).Table 2 Postoperative patients’ characteristics
Characteristics n % M
pT Category pT0 17 21,8% n.r
pT1 8 10,3% n.r
pT2 10 12,8% n.r
pT3 38 48,7% 23
pT4 4 5,1% 10
pN Category pN0 36 46,2% n.r
pN+ 40 51,3% 20
pM Category pM0 74 94,9% n.r
pM1 3 3,8% 21
Grading postop. G1/2 15 19,2% 22
G3/4 33 42,3% 28
Lauren postop. (AEG) Intestinal 22 50,0% 24
Nonintestinal 14 31,8% 21
R Status R0 68 87,2% 29
R1/2 8 10,2% 13
Median Survival shown in months; n.r.: not reached; CI: confidence interval; 3-Y-S: 3
not reached)).Defining histopathological non-responding patients as hav-
ing more than 50% remaining tumor cell mass in histo-
pathological analysis, histopathological non-responders
showed lower tissue levels of Follistatin than patients with
more than 50% remaining tumor cells (p = 0.015).edian Survival (IQR) 95%CI 3-Y-S (%) p Value
. - 54,1% 0,464
. - 72,9%
. - 58,3%
,8 (14,0;*) 14,3 - 33,4 33,8%
,4 (3,9;19,1) 0,0 - 25,2 25,0%
. - 66,1% 0,001
,3 (11,9;33,7) 14,9 - 25,6 21,8%
. - 46,1% 0,235
,8 (3,9;33,7) 0,0 - 73,3 0,0%
,6 (11,6;*) - 48,1% 0,927
,5 (13,7;*) 15,5 - 41,4 40,7%
,0 (19,1;*) 14,6 - 33,3 27,8% 0,796
,1 (13,8;*) 15,7 - 26,6 31,2%
,1 (13,8;*) 15,8 - 42,4 42,7% 0,484
,7 (10,4;*) 0,0 - 27,4 37,5%
-Year-Survival; IQR: inter quartile range (1st quartile; 3rd quartile (* 3rd quartile
Table 3 Correlation of angiogenic factors of the tumor tissue and clinicopathological factors
Characteristics G-CSF PECAM-1 HGF VEGF Leptin PDGF-BB Ang-2 Foll. IL8 Ang2/VEGF
Gender male 6,1 34366,0* 5451,8 39,2 105,5 37,1* 355,0 552,7 59,7 5,7
female 4,2 28126,3* 4166,9 59,0 127,2 26,4* 392,2 712,8 62,9 4,3
Localisation AEG I/II 6,1 27041,8 4848,4 39,2 108,2 33,3 316,1* 408,5* 59,7* 4,7
SCC 8,0 31757,8 5618,5 59,0 127,2 29,1 464,7* 820,1* 59,7* 11,4
Grading G1/2 4,5 32785,4 4042,4 39,2 105,5 35,6 363,2 624,3 37,6 6,2
G3/4 6,6 28933,8 5451,8 49,8 124,5 30,6 379,8 560,4 62,9 5,0
cT Category cT1
cT2 16,4 33440,3 1969,7 80,5 205,3 97,5 105,2 705,9 179,7 1,3
cT3 6,1 29392,7 5394,0 38,1 105,5 33,3 375,1 597,3 39,0 7,6
cT4 6,1 34773,5 11315,6 184,8 111,0 30,2 384,7 342,4 116,6 3,4
cN Category cN0 6,1 34933,9 5440,2 41,8 116,3 29,1 396,4 624,3 38,4 8,5
cN+ 6,1 30954,5 5239,3 47,8 108,2 33,3 353,8 552,7 59,7 5,0
cM Category cM0 6,4 29583,5 5316,6 40,0 113,6 32,9 371,5 578,9 49,4 6,1
cM1 5,9 36863,4 6869,7 61,8 101,4 32,5 358,1 529,7 66,0 1,2
pT Category pT0 4,7 30954,5 4042,4 24,9 89,4 26,8 392,8 712,8 20,4 17,1
pT1 11,0 38189,0 5248,9 55,0 195,0 62,0 223,5 538,1 152,1 4,1
pT2 5,3 30783,3 7546,9 51,6 101,4 37,5 312,6 751,5 119,7 3,8
pT3 6,8 32469,4 6338,5 56,4 116,3 36,2 386,0 486,4 66,0 4,8
pT4 17,3 20880,8 732,2 108,1 108,2 48,7 396,4 101,4 821,3 0,7
pN Category pN0 8,0 33440,3 4848,4 41,8 119,0 33,3 424,8 624,3 59,7 10,1
pN+ 6,1 28126,3 5618,5 43,2 108,2 31,7 353,8 487,5 59,7 4,7
pM Category pM0 6,4 30364,4 5417,1 42,5 109,5 31,9 365,6 557,7 59,7 5,7
pM1 5,4 35429,1 8653,0 161,6 113,7 64,6 456,4 584,1 40,1 19,1
Response
Clinical Resp. 4,7 33440,3 4042,4 41,8 127,2 28,7 424,8 712,8* 37,5 11,4*
Nonresp. 6,6 28709,3 5968,0 45,5 106,8 36,2 365,6 557,7* 61,3 4,9*
Histopathological Resp. 4,7 29774,3 4848,4 25,9 94,7 28,7 392,8 731,1 21,8 11,4*
Nonresp. 6,6 32785,4 6317,4 51,1 116,3 37,1 363,2 487,5 66,2 4,7*
Values are the median values of the particular subgroups in pg/ml; statistically significant factors identified by the Mann–Whitney-U-Test/Kruskal-Wallis-Test are
marked in bold; (significant factors identified by MANOVA are marked with*)Ang-2: Angiopoietin-2; Ang2/VEGF: ratio between Angiopoietin-2 and VEGF.
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To evaluate the prognostic impact of the angiogenic cy-
tokines, Kaplan-Maier survival analysis were performed
for each angiogenic factor with the median as cut-off. In
the patients serum no angiogenic cytokine was found to
be associated with survival time. In the tissue samples
HGF and Follistatin levels were associated with patients’
prognosis (p = 0.037; p = 0.036) (Figures 1A and B). Me-
dian survival of patients with lower levels of HGF was
not reached at time of analysis, while median survival of
patients with higher levels was 20.3 ± 4,3 (11,7 – 28,8
95%CI) months. Median survival of patients with lower
levels of Follistatin was 36,7 months (95% CI not
reached), compared to 16,0 ± 2,7 (10,6 – 21,4 95% CI)
months for patients with higher levels. The median sur-
vival and the significant cytokines for all patients arepresented in Tables 5 and 6. When performing multi-
variate cox regression analysis including all angiogenic
factors in tissue, Follitstatin levels remained associated
to overall survival (p = 0.04).
In AEG tumor tissues alone HGF and Leptin were
found to be associated with patients’ survival (p = 0.028
and p = 0.034) (Additional file 4: Tables S4 A and B). In
SCC alone no angiogenic cytokine in the tumor tissue
reached statistical significance. A lower Angiopoietin-2/
VEGF-Ratio in the serum was associated with longer
survival in patients with SCC (p = 0.032) (Additional file
4: Tables S4 C and D).
Receiver Operating Characteristics (ROC) curves
We performed Receiver Operating Characteristics for
the statistically significant cytokines to determine
Table 4 Correlation of circulating angiogenic factors and clinicopathological factors
Characteristics G-CSF PECAM-1 HGF VEGF Leptin PDGF-BB Ang-2 Foll. IL8 Ang2/VEGF
Gender male 35,7* 3278,0 1016,1 38,4 1468,8 1381,3 869,3 200,4 11,1 21,9
female 35,3* 3052,5 965,2 36,5 2083,6 961,4 802,9 209,1 12,2 21,2
Localisation AEG I/II 35,7 3295,3 1023,4 37,1 1624,9 1185,4 941,6 213,9 12,3 22,3
SCC 36,7 3017,6 921,7 37,1 1079,8 1334,8 776,1 192,7 11,0 20,8
Grading G1/2 37,6 3415,3 950,7 37,1 1474,8 1621,6 869,3 242,9* 12,7 22,1
G3/4 34,8 3260,8 1023,4 38,8 1733,7 1032,3 820,3 196,5* 11,6 22,2
cT Category cT1
cT2 28,3 3364,0* 763,5 38,1 2250,5 1082,1 757,5 188,8 9,0 19,9
cT3 35,7 3156,8* 979,7 36,1 1468,8 1242,4 867,0 199,4 11,3 22,4
cT4 54,4 6421,4* 1318,4 212,2 1114,8 4365,2 1331,2 393,7 14,4 6,6
cN Category cN0 34,8 3260,8 900,1 37,4 1349,8 1088,7 1212,8* 194,6 10,9 20,1
cN+ 35,7 3226,3 1019,8 37,4 1636,9 1387,2 832,0* 205,2 12,3 22,4
cM Category cM0 35,7 3295,3 965,2 38,8 1624,9 1250,7 891,5 215,8 11,6 22,4
cM1 37,6 2663,4 1170,2 29,3 1255,3 1334,8 685,3 183,1 12,3 19,6
pT Category pT0 28,3 2841,5 849,5 38,8 1103,1 1500,6 757,5 221,6 10,9 14,1
pT1 43,7 3260,8 997,9 29,3 2908,3 1175,4 722,6 194,6 10,0 21,6
pT2 37,6 2717,0 1694,2 37,4 2501,2 1418,6 1021,2 201,3 14,1 18,2
pT3 35,7 3398,2 1023,5 33,5 1314,4 1137,1 868,1 210,0 11,3 23,4
pT4 27,3 4136,8 950,7 62,7 3011,1 1427,7 583,1 146,8 9,5 14,7
pN Category pN0 35,7 3226,3 1023,4 50,4 1456,9 1499,8 941,6 204,2 11,0 18,7
pN+ 35,3 3278,0 961,6 32,4 1552,9 1180,4 818,0 210,0 12,2 22,9
pM Category pM0 35,7 3226,3 979,7 36,5 1492,7 1275,1 867,0 209,0 11,3 21,9
pM1 41,3 4136,8 950,7 39,4 1114,8 1088,7 778,4 171,6 12,3 14,7
Response
Clinical Resp. 28,3 3226,3 961,6 44,1 1880,0 1500,6 945,1 194,6 12,3 22,7
Nonresp. 35,7 3295,3 1023,4 36,5 1361,7 1250,7 843,6 204,2 11,6 21,4
Histopathological Resp. 34,3 3017,6 921,7 37,8 1733,7 1500,6 727,2 194,6 11,0 18,1
Nonresp. 35,7 3278,0 1045,4 35,1 1468,8 1225,6 891,5 209,0 12,2 22,4
Values are the median values of the particular subgroups in pg/ml; significant factors identified by MANOVA are marked with *; (no statistically significant factors
were identified by the Mann–Whitney-U-Test/Kruskal-Wallis-Test); Ang-2: Angiopoietin-2; Ang2/VEGF: ratio between Angiopoietin-2 and VEGF.
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median. The calculated optimal cut-offs are similar to
the ones using the median as cut-off. Receiver operat-
ing charateristics with the optimal cut-offs, sensitivity
and specificity are shown in Table 7.
Discussion
In this study a panel of angiogenic factors in neoadju-
vantly treated patients with esophageal cancer (AEGI/
II and SCC) that underwent tumor resection in the
Department of Surgery at the University of Heidelberg
was analyzed in the tumor tissue and serum. Of the
angiogenic factors VEGF, Angiopoietin-2, PECAM-1,
Follistatin, Leptin, G-CSF, HGF, PDGF-BB and IL-8,
two angiogenic factors (HGF and Follistatin) are asso-
ciated with esophageal cancer patients’ prognosis inposttherapeutic tumor tissue. Expression levels of
most angiogenic factors in AEG and SCC were similar,
biological differences of these two entities of esopha-
geal cancer with respect to angiogenesis are indicated
by the different expression of Angiopoietin-2 and Fol-
listatin. No association with response to neoadjuvant
therapy could be observed.
Results of this study are of current importance as anti-
angiogenic therapy has found its way into clinical ther-
apy regimens. As a result the complex interactions in
the tumor microenvironment and the role of angiogen-
esis within it receive more and more interest. It has yet
to be determined if the angiogenic microenvironment
influences neoadjuvant therapy response in esophageal
cancer patients. Currently reliable clinical or molecular
markers to evaluate response are still lacking, even
Figure 1 Prognostic cytokines in the tissue of esophageal
cancer patients. Kaplan-Maier plots for overall survival of
esophageal cancer patients according to A) tissue protein levels
of HGF (smaller and higher then median of 5417,1 pg/ml) and B)
tissue protein levels of follistatin (smaller and higher then median
of 557,7 pg/ml) (n = 58; p < 0.05).
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evaluated as a method [25]. Response prediction is be-
coming of exceeding interest especially in regard to the
chosen therapeutical regimen considering that response
rates to classical chemo(radio)therapeutical regimens do
mostly not exceed 50% [7]. This analysis of the angio-
genic phenotype within the tumor and its tumor micro-
environment and its relation to therapy response adds
further insight into this problem. As key hallmark of
cancer, angiogenesis is activated early in tumorigenesis
and contributes to tumor progression and metastasis by
influencing and shaping the tumor microenvironment
[11]. The “angiogenic switch” occurs when the balancebetween pro- and anti-angiogenic factors is shifted to-
wards the pro-angiogenic side, resulting in increased
angiogenesis and tumor growth [26]. In esophageal can-
cers angiogenesis has been described to be involved in
tumor growth and metastasis [17] and the prototypic
angiogenic factor VEGF is often associated with poor
survival. Other pro-angiogenic factors such as HGF, FGF
and IL-8 have been reported to play a role in esophageal
cancer [18,27]. However most studies were limited to
one or two investigated factors, curbing conclusions
about the complex network of different angiogenic fac-
tors. A strength of our study is the analysis of a compre-
hensive angiogenic factor panel in both blood and
corresponding tumor tissue in most of the patients. Fur-
thermore all included patients underwent neoadjuvant
treatment.
Limitations of our study are the limited number of pa-
tients and the retrospective design, with all its known
and accepted problems. Furthermore, all esophageal can-
cer entities are analyzed together, which might be criti-
cized by some groups, despite the fact that the UICC
classification [28] and landmark studies like the CROSS
Study [5,29] also combine them. To address this issue
we additionally provided subgroup analysis. As further
limitations both tumor and serum samples was available
in only 70% of the patients and different preoperative
treatment regimens were applied, although both are ac-
cepted standards in esophageal cancer [4-6,30,31].
We found that in the tumor tissue Follistatin and
Angiopoietin-2 are differentially expressed between the
two tumor types with significantly higher median tissue
levels of the two angiogenic factors in SCC patients
when compared to AEG patients. These general differ-
ences in expression support the hypothesis that AEG
and SCC represent cancer types with at least some bio-
logical differences in angiogenesis. Similarly differences
in etiology, epidemiology and tumor biology between
AEG and SCC have been reported before [2], but both
tumor entities are classified identically within UICC
2010 [28] and analyzed together in most studies [5].
Hepatocyte Growth Factor (HGF) and Follistatin in
the tumor tissue were associated with patient survival.
Using the median as cut-off, high HGF and Follistatin
expression in the tumor tissue were associated with poor
patients’ prognosis. ROC analysis aimed to evaluate if a
more appropriate cut-off value then the median should
be used. However the calculated “optimal” cut-off values
were actually close to the used median and support its
use as cut-off value in this study. The low value of the
AUC is likely related to the small sample size for this
calculation, however it underlines the need of additional
larger studies in the future.
HGF and its receptor c-Met play an important role in
the development of various cancer types. HGF, also
Table 5 Prognostic value of angiogenic factors in the tumor tissue
Tissue factor Median n % Median survival (IQR) 95% CI 3-Y-S (%) p Value
G-CSF 6,1 ≤ Median 30 51,7% 33,7 (17,0;*) 15,7 - 51,8 40,6% 0,181
> Median 28 48,3% 14,0 (10,5;*) 2,5 - 25,6 32,1%
PECAM-1 31356,1 < Median 29 50,0% 29,1 (12,3;*) - 47,9% 0,251
> Median 29 50,0% 22,6 (11,9;*) 13,9 - 31,3 28,7%
HGF 5417,1 < Median 29 50,0% n.r. - 51,3% 0,037
> Median 29 50,0% 20,3 (10,9;36,7) 11,7 - 28,8 24,2%
VEGF 42,5 < Median 29 50,0% 23,8 (17,0;*) 12,9 - 34,8 36,6% 0,475
> Median 29 50,0% 22,6 (10,5;*) 0,0 - 47,7 36,9%
Leptin 109,5 < Median 29 50,0% 22,6 (14,0;*) 4,0 - 41,3 40,6% 0,420
> Median 29 50,0% 21,7 (10,9;*) 4,8 - 38,7 33,1%
PDGF-BB 32,5 < Median 29 50,0% 28,5 (14,0;*) 19,0 - 38,0 32,3% 0,777
> Median 29 50,0% 21,7 (10,9;*) 10,4 - 32,9 40,3%
Angiopoietin-2 371,5 < Median 29 50,0% 22,6 (11,9;*) 1,3 - 44,0 40,3% 0,712
> Median 29 50,0% 23,8 (12,3;*) 9,7 - 37,9 34,5%
Follistatin 557,7 < Median 29 50,0% 36,7 (19,1;*) - 47,9% 0,036
> Median 29 50,0% 16,0 (10,9;*) 10,6 - 21,4 26,2%
IL-8 59,7 ≤ Median 30 51,7% 21,7 (13,8;*) 2,8 - 40,7 41,0% 0,431
> Median 28 48,3% 22,6 (10,5;*) 12,1 - 33,1 32,5%
Ang-2/VEGF-Ratio 5,7 < Median 29 50,0% 33,7 (11,9;*) - 46,0% 0,594
> Median 29 50,0% 21,7 (13,8;*) 11,7 - 31,8 30,0%
Median survival shown in months; n.r.: not reached; CI: confidence interval; 3-Y-S: 3-Year-Survival; IQR: inter quartile range (1st quartile; 3rd quartile (* 3rd quartile
not reached)); statistically significant factors are marked in bold.
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epithelial cells that is active in embryogenesis and medi-
ates defense to tissue damage in adults. HGF binds c-
Met, a tyrosine kinase receptor as exclusive ligand in-
duces the activation of oncogenic pathways, angiogenesis
and scattering of cells, leading to metastasis [32]. Sup-
porting our findings concerning HGF, Tuynman et al.
found Met expression to be an independent prognostic
risk factor in esophageal adenocarcinoma [33]. Further-
more, it has been reported that higher HGF levels in
serum and tissue are associated with tumor progression
and poor survival in esophageal squamous cell carcin-
oma [19,20]. Ren et al. found pretherapeutic HGF levels
as an independent prognostic factor [19]. In our data we
did not find a correlation of HGF in the patients’ sera
with survival. This could be due to the point of time
when the blood sampling took place. Neoadjuvant ther-
apy may influence HGF serum levels in a different way
than in the tumor tissue.
Follistatin tissue levels were significantly associated
with patients’ prognosis. Elevated levels of Follistatin as
an antagonist of the TGFβ superfamily member Activin
A have been reported in solid tumors [34-37], however
no data on esophageal cancer have been published so
far. Interestingly tissue levels of Follistatin differedbetween non-responders and responders, when defining
responders as having less than 50% remaining tumor cell
mass (p = 0.015). The definitions of histopathological re-
sponse after chemotherapy or radiochemotherapy are
heterogenous varying from a pCR up to 50% residual
tumor and would need clear definitions to make study
results comparable.
We investigated angiogenic cytokine levels with regard
to patients’ clinical and histopathological response and
prognosis. Considering the fact that all patients received
neoadjuvant chemo(radio)therapy it is interesting that
we found no association between circulating angiogenic
cytokines and patients survival or response. This could
be related to the point in time of posttherapeutic meas-
urement of the factors. Neoadjuvant therapy might influ-
ence circulating angiogenic cytokine levels and thus
change levels after chemo(radio)therapy. Most studies
investigated angiogenic factors in previously untreated
patients [19,38-41].
Based on these interesting obtained results we would
recommend a prospective validation of this data in a
patient cohort from multiple centers. If the results are
confirmed a large multicenter trial with a central bio-
banking should be performed. This should be included
within the next trials on neoadjuvant or perioperative
Table 6 Prognostic impact of serum angiogenic factors
Serum factor Median n % Median survival (IQR) 95% CI 3-Y-S (%) p value
G-CSF 35,7 ≤ Median 41 55,4% 23,0 (12,8;*) 12,8 - 33,2 40,6% p = 0,669
> Median 32 43,2% 30,6 (16,0;*) 16,2 - 45,0 43,5%
PECAM-1 3243,5 < Median 37 50,0% 29,1 (12,8;*) 17,1 - 41,1 44,5% p = 0,994
> Median 37 50,0% 28,5 (17,0;*) 12,3 - 44,7 40,8%
HGF 979,7 ≤ Median 37 50,0% 30,6 (12,8;*) 12,9 - 48,3 43,0% p = 0,871
> Median 36 48,6% 28,5 (13,7;*) 15,7 - 41,3 41,1%
VEGF 37,1 < Median 36 48,6% 23,0 (12,3;*) 12,9 - 33,1 39,8% p = 0,590
> Median 36 48,6% 33,7 (16,0;*) 14,8 - 52,6 44,3%
Leptin 1492,7 ≤ Median 37 50,0% 30,6 (14,0;*) 16,5 - 44,7 43,5% p = 0,800
> Median 36 48,6% 28,5 (11,6;*) 10,0 - 47,0 41,6%
PDGF-BB 1275,1 < Median 37 50,0% 23,8 (12,3;*) 14,3 - 33,3 39,6% p = 0,396
> Median 37 50,0% 36,7 (18,8;*) - 46,2%
Angiopoietin-2 867,0 ≤ Median 37 50,0% 29,1 (16,0;*) 18,8 - 39,4 44,7% p = 0,606
> Median 36 48,6% 28,5 (11,6;*) 11,2 - 45,8 39,7%
Follistatin 200,37 < Median 37 50,0% 30,6 (16,0;*) - 47,4% p = 0,416
> Median 37 50,0% 23,8 (12,8;*) 7,1 - 40,5 38,3%
IL-8 11,86 < Median 37 50,0% n.r. - 51,5% p = 0,143
> Median 37 50,0% 21,7 (12,3;*) 17,3 - 26,1 32,6%
Ang-2/VEGF-Ratio 21,9 < Median 36 48,6% 33,7 (19,1;*) 14,9 - 52,5 44,3% p = 0,379
> Median 36 48,6% 23,0 (11;*) 11,6 - 34,4 39,0%
Median survival shown in months; n.r.: not reached; CI: confidence interval; 3-Y-S: 3-Year-Survival; ; IQR: inter quartile range (1st quartile; 3rd quartile
(* 3rd quartile not reached)).
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samples in a standardized manner, pre-therapeutic, during
therapy, before surgery and during the follow up. Tumor
tissue could also be obtained during initial biopsy and from
the pathological sample. With this information it will be
possible to provide a more complete picture of the tumor
biology. The aim will be to identify deregulated targetable
pathways as i.e. the HGF/met pathway.
In summary, further studies will be necessary to investi-
gate the impact of neoadjuvant therapy on tumor
microenvironment and circulating angiogenic cytokines.
Pretherapeutic and preoperative blood sampling could elu-
cidate the change of angiogenic factor levels over time of
therapy. As the limited number of patients may have influ-
enced the results of this study, investigations in larger pa-
tient cohorts could confirm our findings and evaluate
angiogenic cytokine levels as pretherapeutic diagnostic fac-
tors – helping the physician to choose the right therapy.Table 7 Receiver Operating Characteristics (ROC) for relevant
Tissue factor Median Sensitivity/specificity
HGF 5417,09 63,6/68
Follistatin 557,66 60,6/64
Median / Best cut-point values in pg/ml; AUC: area under the curve.Conclusion
Angiogenic cytokines seem to play an important
role in patients with esophageal cancer. In this study
two angiogenic factors (HGF and Follistatin) in
tumor tissue after neoadjuvant therapy were associ-
ated with esophageal cancer patients’ prognosis. HGF
levels seem to be important with regard to tumor
development in esophageal cancer. Different expres-
sion of angiogenic cytokines in AEG and SCC
subgroups confirm the assumption that the two rep-
resent different entities with respect to angiogenesis.
The lack of association with response to therapy
could be explained by the fact that samples were
collected at a preoperative and not pretherapeutic
point. Results are promising and should be pursued
prospectively in a pre- and posttherapeutic state.
Further studies with larger number of patients seem
to be necessary.factors
Best cut-point Sensitivity/specificity AUC
5316,62 66,7/68 0,697
666,22 54,5/72 0,568
Dreikhausen et al. BMC Cancer  (2015) 15:121 Page 10 of 11Additional files
Additional file 1: Table S1. A) neoadjuvant treatment regimens. B)
operative procedures.
Additional file 2: Table S2. Response to neoadjuvant therapy.
Additional file 3: Table S3. Association of angiogenic cytokines with
clinical response and tumor regression grade (TRG) in AC and SCC.
Additional file 4: Table S4. A) Prognostic significance of circulating
angiogenic factor levels in AEG I/II. B) Prognostic significance of tissue
angiogenic factor levels in AEG I/II. C) Prognostic significance of
circulating angiogenic factor levels in SCC. D) Prognostic significance of
tissue angiogenic factor levels in SCC.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LK, SB, LS, NG, CF, KO and TS contributed to the study design. Data
acquisition was carried out by LD, SB, LS, UH, WW, DJ, LG, CF, KO and TS.
LD, SB, TB, SF, KO and TS contributed to data analysis. LD, KO and TS drafted
the manuscript and SB, LS, UH, WW, DJ, TB, NG, LG and CF reviewed the
manuscript. All authors read and approved the final version of the manuscript.
Acknowledgements
The authors thank the Heidelberg Surgery Foundation for the funding of
this project. This study was approved by the local ethics commission. We
acknowledge financial support by Deutsche Forschungsgemeinschaft and
Ruprecht-Karls-Universität Heidelberg within the funding programme Open
Access Publishing.
Author details
1Department of General, Visceral and Transplantation Surgery, University of
Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.
2Department of Pathology, University of Heidelberg, 69120 Heidelberg,
Germany. 3National Center of Tumor Diseases, University of Heidelberg,
69120 Heidelberg, Germany. 4Institute of Medical Biometry, University of
Heidelberg, Heidelberg, Germany. 5Department of Diagnostic and
Interventional Radiology, University Hospital Heidelberg, Heidelberg,
Germany. 6Institute for Transplant Immunology, Hannover Medical School,
Hannover, Germany.
Received: 24 June 2014 Accepted: 24 February 2015
References
1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma.
Lancet. 2013;381(9864):400–12.
2. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus
the same disease? Semin Radiat Oncol. 2007;17(1):38–44.
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–52.
4. Cunningham D, Allum W, Stenning S, Thompson J, Van de Velde C,
Nicolson M. Perioperative chemotherapy versus surgery alone for resectable
gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
5. van Hagen PHM, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen
MI, Wijnhoven BPRD, Nieuwenhuijzen GA, et al. Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J Med.
2012;366:2074–84.
6. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A,
et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for
resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol.
2011;12(7):681–92.
7. Blank S, Stange A, Sisic L, Roth W, Grenacher L, Sterzing F, et al.
Preoperative therapy of esophagogastric cancer: the problem of
nonresponding patients. Langenbecks Arch Surg. 2012;398(2):211–20.
8. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, et al. Long-
term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial
comparison of chemotherapy followed by surgery compared with surgery alone
for esophageal cancer. J Clin Oncol. 2007;25(24):3719–25.9. Brucher BL, Stein HJ, Zimmermann F, Werner M, Sarbia M, Busch R, et al.
Responders benefit from neoadjuvant radiochemotherapy in esophageal
squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg
Oncol. 2004;30(9):963–71.
10. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid
tumor microenvironment. J Natl Cancer Inst. 2007;99(19):1441–54.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646–74.
12. Hanahan D, Folkman J. Patterns and emerging mechanisms of the
angiogenic switch during tumorigenesis. Cell. 1996;86(3):353–64.
13. Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic
therapy and development of third-generation anti-angiogenic drug candidates.
Genes Cancer. 2010;1(1):12–25.
14. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical
applications. Biochem Pharmacol. 2001;61(3):253–70.
15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W,
et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.
16. Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in
esophagogastric adenocarcinoma. Oncologist. 2011;16(6):844–58.
17. Oshima Y, Yajima S, Yamazaki K, Matsushita K, Tagawa M, Shimada H.
Angiogenesis-related factors are molecular targets for diagnosis and
treatment of patients with esophageal carcinoma. Ann Thorac Cardiovasc
Surg. 2010;16(6):389–93.
18. Chen M, Cai E, Huang J, Yu P, Li K. Prognostic value of vascular
endothelial growth factor expression in patients with esophageal
cancer: a systematic review and meta-analysis. Cancer Epidemiol
Biomarkers Prev. 2012;21(7):1126–34.
19. Ren Y, Cao B, Law S, Xie Y, Lee PY, Cheung L, et al. Hepatocyte growth
factor promotes cancer cell migration and angiogenic factors expression:
a prognostic marker of human esophageal squamous cell carcinomas. Clin
Cancer Res. 2005;11(17):6190–7.
20. Takada N, Yano Y, Matsuda T, Otani S, Osugi H, Higashino M, et al.
Expression of immunoreactive human hepatocyte growth factor in human
esophageal squamous cell carcinomas. Cancer Lett. 1995;97(2):145–8.
21. Xu Z, Wang S, Wu M, Zeng W, Wang X, Dong Z. TGFbeta1 and HGF protein
secretion by esophageal squamous epithelial cells and stromal fibroblasts in
oesophageal carcinogenesis. Oncol Lett. 2013;6(2):401–6.
22. Han B, Liu J, Ma MJ, Zhao L. Clinicopathological significance of heparanase
and basic fibroblast growth factor expression in human esophageal cancer.
World J Gastroenterol. 2005;11(14):2188–92.
23. Sugiura K, Ozawa S, Kitagawa Y, Ueda M, Kitajima M. Co-expression of aFGF
and FGFR-1 is predictive of a poor prognosis in patients with esophageal
squamous cell carcinoma. Oncol Rep. 2007;17(3):557–64.
24. Heger U, Bader F, Lordick F, Burian M, Langer R, Dobritz M, et al. Interim
endoscopy results during neoadjuvant therapy for gastric cancer
correlate with histopathological response and prognosis. Gastric
Cancer. 2014;17(3):478–88.
25. Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, et al.
Molecular imaging of proliferation and glucose utilization: utility for
monitoring response and prognosis after neoadjuvant therapy in locally
advanced gastric cancer. Ann Surg Oncol. 2011;18(12):3316–23.
26. Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin
Cancer Biol. 2009;19(5):329–37.
27. Diakowska D. Cytokines association with clinical and pathological changes
in esophageal squamous cell carcinoma. Dis Markers. 2013;35(6):883–93.
28. Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Cancer of the esophagus
and esophagogastric junction: data-driven staging for the seventh edition
of the American Joint Committee on Cancer/International Union Against
Cancer Cancer Staging Manuals. Cancer. 2010;116(16):3763–73.
29. Oppedijk V, van der Gaast A, van Lanschot JJ, van Hagen P, van Os R,
van Rij CM, et al. Patterns of recurrence after surgery alone versus
preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin
Oncol. 2014;32(5):385–91.
30. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S,
et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)
for patients with metastatic adenocarcinoma of the stomach or
esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft
Internistische Onkologie. Ann Oncol. 2008;19(11):1882–7.
31. Boige V, Pignon J, Saint-Aubert B. Final results of a randomized trial
comparing preoperative 5-Fluorouracil (F)/cisplatin (P) to surgery alone
Dreikhausen et al. BMC Cancer  (2015) 15:121 Page 11 of 11in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-
FFCD 9703 trial. J Clin Oncol (supplement). 2007;25(18 Suppl):15123.
32. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis,
motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915–25.
33. Tuynman JB, Lagarde SM, Ten Kate FJ, Richel DJ, van Lanschot JJ. Met
expression is an independent prognostic risk factor in patients with
oesophageal adenocarcinoma. Br J Cancer. 2008;98(6):1102–8.
34. Yuen MF, Norris S, Evans LW, Langley PG, Hughes RD. Transforming growth
factor-beta 1, activin and follistatin in patients with hepatocellular
carcinoma and patients with alcoholic cirrhosis. Scand J Gastroenterol.
2002;37(2):233–8.
35. Ren P, Chen FF, Liu HY, Cui XL, Sun Y, Guan JL, et al. High serum levels of
follistatin in patients with ovarian cancer. J Int Med Res. 2012;40(3):877–86.
36. Tumminello FM, Badalamenti G, Fulfaro F, Incorvaia L, Crescimanno M,
Flandina C, et al. Serum follistatin in patients with prostate cancer
metastatic to the bone. Clin Exp Metastasis. 2010;27(8):549–55.
37. Blank S, Deck C, Dreikhausen L, Weichert W, Giese N, Falk C, et al.
Angiogenic and growth factors in gastric cancer. J Surg Res. 2014 Nov 26.
[Epub ahead of print].
38. Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD. IL-6 expression predicts
treatment response and outcome in squamous cell carcinoma of the
esophagus. Mol Cancer. 2013;12:26.
39. Shimada H, Takeda A, Nabeya Y, Okazumi SI, Matsubara H, Funami Y,
et al. Clinical significance of serum vascular endothelial growth factor in
esophageal squamous cell carcinoma. Cancer. 2001;92(3):663–9.
40. Mobius C, Freire J, Becker I, Feith M, Brucher BL, Hennig M, et al. VEGF-C
expression in squamous cell carcinoma and adenocarcinoma of the
esophagus. World J Surg. 2007;31(9):1768–72. discussion 1773–1764.
41. Diakowska D, Krzystek-Korpacka M, Markocka-Maczka K, Diakowski W,
Matusiewicz M, Grabowski K. Circulating leptin and inflammatory response
in esophageal cancer, esophageal cancer-related cachexia-anorexia
syndrome (CAS) and non-malignant CAS of the alimentary tract.
Cytokine. 2010;51(2):132–7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
